A Multi-center pilot study of the effect of Sorafenib on Portal Pressure in Patients with Cirrhosis, Significant Portal Hypertension and Hepatocellular Carcinoma


Hepatocellular Carcinoma | Liver

What is the purpose of this trial?

You are free to choose not to participate and if you do become a subject you are free to withdraw from this study at any time during its course. If you choose not to participate or if you withdraw it will not harm your relationship with your own doctors or with Yale-New Haven hospital. If you do become a subject, you are free to stop and withdraw from this study at any time during its course. If you sign this authorization, you may change your mind at any time, but the researchers may continue to use information collected before you changed your mind to complete the research. To withdraw, you can call a member of the research team at any time and tell them that you no longer want to take part. This will cancel any appointments in the future. You must also follow up your phone call by sending a written notice to revoke this authorization to the principal investigator, Dr. Strazzabosco, Internal Medicine - Digestive Diseases, PO BOX 208019, New Haven, CT 06520-8019. Before you make your decision, a member of the research team will be available so that you can ask any questions you have about the research project. You can ask for any information you want. Sign the consent form only after you have had a chance to ask your questions and have received satisfactory answers If you decide to withdraw from this project, please notify a member of the research team before you withdraw. This notice will allow that person or the research supervisor to inform you if there are any health risks or special requirements linked to withdrawing.

Participation Guidelines

20 Years - 75 Years

Click here for detailed information about who can participate in this trial.

Onyx Pharmaceuticals
Yale Cancer Center
Last Updated:
Study HIC#: